Drug Trial Radar · NCT01476787
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,030
Actual
Start
Dec 29, 2011
Primary completion
Apr 30, 2024
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- The Lymphoma Academic Research Organisation
- First posted
- Nov 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.
Conditions
- Follicular Lymphoma
Interventions
RituximabDrug
375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
LenalidomideDrug
20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
Rituximab-CHOPDrug
7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Rituximab-CVPDrug
7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Rituximab-BendamustineDrug
7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central ReviewTime frame: At 120 weeks
- Progression-free Survival (PFS)Time frame: From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months).
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
Local Institution - 54103
Chandler, Arizona
Local Institution - 51803
Fullerton, California
Local Institution - 52003
Los Angeles, California
Local Institution - 51603
Colorado Springs, Colorado
Local Institution - 52503
Englewood, Florida
Local Institution - 51703
Orlando, Florida
Local Institution - 53803
St. Petersburg, Florida
Local Institution - 50803
Chicago, Illinois
Local Institution - 52203
Lexington, Kentucky
Local Institution - 53603
Westminster, Maryland
Local Institution - 50403
Boston, Massachusetts
Local Institution - 50503
Boston, Massachusetts
Local Institution - 53003
Southfield, Michigan
Local Institution - 51003
St Louis, Missouri
Local Institution - 54403
Cherry Hill, New Jersey
Local Institution - 53703
Hackensack, New Jersey
Local Institution - 50903
Morristown, New Jersey
Local Institution - 54303
Sparta, New Jersey
Local Institution - 52403
New York, New York
Local Institution - 50203
New York, New York
Local Institution - 51303
Nashville, Tennessee
Local Institution - 51203
Dallas, Texas
Local Institution - 51103
Houston, Texas
Local Institution - 54003
Lubbock, Texas
Local Institution - 53303
Richmond, Virginia
Local Institution - 52703
Seattle, Washington
Local Institution - 40922
Fukuoka, Japan
Local Institution - 40422
Hiroshima, Japan
Local Institution - 40122
Isehara City, Kanagawa, Japan
Local Institution - 40322
Kobe, Japan
Local Institution - 40622
Kyoto, Japan
Local Institution - 41022
Sendai, Japan
Local Institution - 40522
Shizuoka, Japan
Local Institution - 40722
Chuo-ku, Tokyo, Japan
Local Institution - 40222
Koto-ku, Tokyo, Japan
Local Institution - 41122
Minato-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.